2010
DOI: 10.1016/s0065-2423(10)51004-7
|View full text |Cite
|
Sign up to set email alerts
|

EGFR and KRAS in Colorectal Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
70
0
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 110 publications
(77 citation statements)
references
References 95 publications
6
70
0
1
Order By: Relevance
“…Together, these results indicate that concurrent upregulation of the growth factor and non-canonical Wnt pathways spurred by Daple is associated with poorer clinical outcomes. Findings are in keeping with a working model (see legend Fig 6F) in which G protein signaling via Daple can be triggered by both growth factor and non-canonical Wnt cascades, two pathways that are frequently upregulated during oncogenic progression and are known to promote tumor cell dissemination (28, 46). …”
Section: Resultssupporting
confidence: 85%
“…Together, these results indicate that concurrent upregulation of the growth factor and non-canonical Wnt pathways spurred by Daple is associated with poorer clinical outcomes. Findings are in keeping with a working model (see legend Fig 6F) in which G protein signaling via Daple can be triggered by both growth factor and non-canonical Wnt cascades, two pathways that are frequently upregulated during oncogenic progression and are known to promote tumor cell dissemination (28, 46). …”
Section: Resultssupporting
confidence: 85%
“…It is well known that tumor immunotherapy is to eliminate tumor cells by activating immune system, while EBV-associated NPC traditional immunotherapy is based on the function of autologous CTL activity (Chua et al, 2001;Leen et al, 2009). On the other hand, B cell mediated humoral immune response also plays an indispensable role, such as neutralization, opsonization and ADCC effects (Chao et al, 2010;Rhodes et al, 2010;Markman et al, 2010). So it would be a good approach to improve the efficacy of a candidate therapeutic vaccine to induce specific cellular and humoral immune coresponse against EBV associated malignancies.…”
Section: Discussionmentioning
confidence: 99%
“…These oligonucleotides are complimentary to genes on the array and allow the measurement of particular gene expression profiles with high sensitivity. This array is unable to predict and analyze unknown genes, as their sequences need to be known for the manufacture of the [219] PSA [220] Cyclooxygenasearachidonic acid metabolites [221] 2000 cell surface protein cluster in cancer [222] Ovarian BRCA1 BRCA2 mutations [223] CpG-island hypermethylation (BRCA1) [224] Prostasin [225] HE4 [226] Ca125 [227] Eosinophil-derived neurotoxin and COOHterminal osteopontin [228] Breast BRCA1 BRCA2 mutations [223] CpG-island hypermethylation (BRCA1, E-cadherin, TMS1 and estrogen receptor) [229] EpCAM, CD45 [230] Pancreatic Palladin mutation [231] BNC1 ADAMTS1 methylation [232] A1-antitrypsin Apolipoprotein A1 [233] Gastric PTEN mutation [234] CpG-island hypermethylation (hMLH1 and p14ARF) [235] miR-1, miR20a, miR-27a, miR-34 and miR-423-5p expression [236] Hepatocellular RASSF1A, SSBP2 and B4GALT1 hypermethylation [237] AFP-L3 [238] Colorectal CpG-island hypermethylation, hypermethylation of miRNAs (miR-124a) [239] p53 expression [239], EGFR-related KRAS [240], c-MET, b-catenin [241] CEA [242] Smaller number of combinational molecular phenotype cluster in cancer [167] Some of these biomarkers are currently in clinical practice. AFP: Alpha feto-protein; CEA: Carcino-embryonic antigen; PSA: Prostate specific antigen.…”
Section: Genomicsmentioning
confidence: 99%